Publications

• Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors.

  (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE.) J Natl Cancer Inst. 2021 Sep 07 PMID: 34491344 09/08/2021

• Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.

  (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplant. 2021 08;56(8):1998-2004 PMID: 33824440 SCOPUS ID: 2-s2.0-85103674051 04/08/2021

• Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.

  (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V.) Leuk Lymphoma. 2021 07;62(7):1730-1739 PMID: 33648418 SCOPUS ID: 2-s2.0-85110241807 03/03/2021

• Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?

  (Badar T, Atallah E.) Expert Opin Investig Drugs. 2021 Jun;30(6):665-673 PMID: 33836635 SCOPUS ID: 2-s2.0-85104939879 04/11/2021

• Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.

  (Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E.) Cancer. 2021 Apr 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020

• Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making.

  (Atallah EL.) Best Pract Res Clin Haematol. 2021 03;34(1):101240 PMID: 33762095 SCOPUS ID: 2-s2.0-85100148584 03/26/2021

• Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

  (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplantation. August 2021;56(8):1998-2004 SCOPUS ID: 2-s2.0-85103674051 08/01/2021

• Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making

  (Atallah EL.) Best Practice and Research: Clinical Haematology. March 2021;34(1) SCOPUS ID: 2-s2.0-85100148584 03/01/2021

• Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.

  (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE.) JAMA Oncol. 2021 Jan 01;7(1):42-50 PMID: 33180106 PMCID: PMC7662490 SCOPUS ID: 2-s2.0-85096163350 11/13/2020

• Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

  (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS.) Leuk Lymphoma. 2021 01;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020

• Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

  (Atallah E, Schiffer CA.) Haematologica. 2020 12 01;105(12):2738-2745 PMID: 33054106 PMCID: PMC7716356 SCOPUS ID: 2-s2.0-85093538868 10/16/2020

• Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study

  (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M.) Leukemia Research. August 2020;95 SCOPUS ID: 2-s2.0-85085967271 08/01/2020